Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of OB756 tablets for steroid-refractory or steroid-dependent moderate to severe graft-versus-host disease
CTR20220555Phase 2Active
- Sponsor
- Hangzhou Bangshun Pharmaceutical
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bewintinib in Acute Graft-Versus-Host Disease (aGvHD), chronic graft-versus-host disease (cGVHD), sponsored by Hangzhou Bangshun Pharmaceutical. Started Jun 2022; status: active.
02
Drugs
bewintinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20220555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220555.